

Table S1 Serum T-DM1

Cycle	Time	n	Mean ± SD, µg/mL
1	Pre-dose 15-30 min post-infusion	142/131	NR/76.4±26.9
2	Pre-dose 15-30 min post-infusion	122/122	1.14±1.07/81.8±25.9
3	Pre-dose 15-30 min post-infusion	111/120	2.77±9.13/70.9±20.7
4	Pre-dose 15-30 min post-infusion	114/120	2.53±7.79/69.7±27.4

Patients were included in the PK analysis if they had received at least one dose of T-DM1 and had at least one post-dose serum or plasma result by the data cut-off time for the primary analysis. NR, not reportable; SD, standard deviation.

Table S2 Serum total trastuzumab

Cycle	Time	n	Mean ± SD, µg/mL
1	Pre-dose 15-30 min post-infusion	140/128	NR/80.4±23.9
2	Pre-dose 15-30 min post-infusion	119/119	7.76±9.76/84.1±18.7
3	Pre-dose 15-30 min post-infusion	111/118	9.41±12.0/78.3±21.0
4	Pre-dose 15-30 min post-infusion	111/120	10.4±11.8/77.3±27.9

Patients were included in the PK analysis if they had received at least one dose of T-DM1 and had at least one post-dose serum or plasma result by the data cut-off time for the primary analysis. NR, not reportable; SD, standard deviation.

Table S3 Plasma DM1

Cycle	Time	n	Mean ± SD, ng/mL
1	Pre-dose 15-30 min post-infusion	151/149	NR/14.0±7.06
2	15-30 min post-infusion	146	13.6±7.22
3	15-30 min post-infusion	135	13.1±6.99
4	15-30 min post-infusion	131	13.9±6.29

Patients were included in the PK analysis if they had received at least one dose of T-DM1 and had at least one post-dose serum or plasma result by the data cut-off time for the primary analysis. NR, not reportable, SD, standard deviation.